Non-contrast CT markers of intracerebral hemorrhage expansion: The influence of onset-to-CT time.


Journal

International journal of stroke : official journal of the International Stroke Society
ISSN: 1747-4949
Titre abrégé: Int J Stroke
Pays: United States
ID NLM: 101274068

Informations de publication

Date de publication:
07 2023
Historique:
medline: 29 6 2023
pubmed: 23 11 2022
entrez: 22 11 2022
Statut: ppublish

Résumé

Hematoma expansion (HE) is an appealing therapeutic target in intracerebral hemorrhage (ICH) and non-contrast computed tomography (NCCT) features are promising predictors of HE. We investigated whether onset-to-CT time influences the diagnostic performance of NCCT markers for HE. Retrospective multicentre analysis of patients with primary ICH. The following NCCT markers were analyzed: hypodensities, heterogeneous density, blend sign, and irregular shape. HE was defined as growth ⩾6 mL and/or ⩾33%. We calculated the sensitivity, specificity, positive, and negative predictive values (PPVs and NPVs) of NCCT markers for HE, stratified by onset-to-CT time (<2 h, 2-4 h, 4-6 h, >6 h). We included 1135 patients (median age 69, 53% males), of whom 307 (27%) experienced HE.Overall hypodensities had the highest sensitivity (0.68) and blend sign the highest specificity (0.87) for HE. Hypodensities were more common and had higher sensitivity (0.80) in patients with imaging within 2 h. The same result was observed for heterogeneous density, whereas irregular shape had a similar prevalence across time strata and higher sensitivity (0.79) beyond 6 h from onset. The frequency of blend sign increased with longer onset-to-CT time, whereas its specificity declined after 6 h from onset. The diagnostic performance of NCCT markers is influenced by imaging time. Hypodensities identified four out of five patients with HE within 2 h from onset, whereas irregular shape performed better in late presenters. Our findings may improve the use of NCCT markers in future studies and trials targeting HE.

Sections du résumé

BACKGROUND
Hematoma expansion (HE) is an appealing therapeutic target in intracerebral hemorrhage (ICH) and non-contrast computed tomography (NCCT) features are promising predictors of HE.
AIMS
We investigated whether onset-to-CT time influences the diagnostic performance of NCCT markers for HE.
METHODS
Retrospective multicentre analysis of patients with primary ICH. The following NCCT markers were analyzed: hypodensities, heterogeneous density, blend sign, and irregular shape. HE was defined as growth ⩾6 mL and/or ⩾33%. We calculated the sensitivity, specificity, positive, and negative predictive values (PPVs and NPVs) of NCCT markers for HE, stratified by onset-to-CT time (<2 h, 2-4 h, 4-6 h, >6 h).
RESULTS
We included 1135 patients (median age 69, 53% males), of whom 307 (27%) experienced HE.Overall hypodensities had the highest sensitivity (0.68) and blend sign the highest specificity (0.87) for HE. Hypodensities were more common and had higher sensitivity (0.80) in patients with imaging within 2 h. The same result was observed for heterogeneous density, whereas irregular shape had a similar prevalence across time strata and higher sensitivity (0.79) beyond 6 h from onset. The frequency of blend sign increased with longer onset-to-CT time, whereas its specificity declined after 6 h from onset.
CONCLUSION
The diagnostic performance of NCCT markers is influenced by imaging time. Hypodensities identified four out of five patients with HE within 2 h from onset, whereas irregular shape performed better in late presenters. Our findings may improve the use of NCCT markers in future studies and trials targeting HE.

Identifiants

pubmed: 36412236
doi: 10.1177/17474930221142742
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

704-711

Auteurs

Andrea Morotti (A)

Neurology Unit, Department of Neurological Sciences and Vision, ASST Spedali Civili, Brescia, Italy.

Qi Li (Q)

Department of Neurology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Valentina Mazzoleni (V)

Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Owensboro, Italy.

Jawed Nawabi (J)

Department of Radiology (CCM), Berlin Institute of Health, Campus Mitte, Charité-Universitätsmedizin Berlin, Humboldt-Universität zu Berlin and Freie Universität Berlin, Berlin, Germany.
BIH Biomedical Innovation Academy, Berlin Institute of Health (BIH), Berlin, Germany.

Frieder Schlunk (F)

BIH Biomedical Innovation Academy, Berlin Institute of Health (BIH), Berlin, Germany.
Department of Neuroradiology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Federico Mazzacane (F)

Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
U.C. Malattie Cerebrovascolari e Stroke Unit, IRCCS Fondazione Mondino, Pavia, Italy.

Giorgio Busto (G)

Neuroradiology Unit, Department of Radiology, Careggi University Hospital, Florence, Italy.

Elisa Scola (E)

Neuroradiology Unit, Department of Radiology, Careggi University Hospital, Florence, Italy.

Laura Brancaleoni (L)

IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Neurologia e Rete Stroke Metropolitana, Ospedale Maggiore, Bologna, Italy.

Sebastiano Giacomozzi (S)

IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Neurologia e Rete Stroke Metropolitana, Ospedale Maggiore, Bologna, Italy.

Luigi Simonetti (L)

IRCCS Istituto delle Scienze Neurologiche di Bologna, UO (SSI) di Neuroradiologia, Ospedale Maggiore, Bologna, Italy.

Michele Laudisi (M)

Clinica Neurologica, Dipartimento di Scienze Biomediche e Chirurgico Specialistiche, Università degli studi di Ferrara and Ospedale Universitario S. Anna, Ferrara, Italy.

Anna Cavallini (A)

U.C. Malattie Cerebrovascolari e Stroke Unit, IRCCS Fondazione Mondino, Pavia, Italy.

Andrea Zini (A)

IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Neurologia e Rete Stroke Metropolitana, Ospedale Maggiore, Bologna, Italy.

Ilaria Casetta (I)

Clinica Neurologica, Dipartimento di Scienze Biomediche e Chirurgico Specialistiche, Università degli studi di Ferrara and Ospedale Universitario S. Anna, Ferrara, Italy.

Enrico Fainardi (E)

Neuroradiology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.

Dar Dowlatshahi (D)

Division of Neurology, Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.

Alessandro Padovani (A)

Neurology Unit, Department of Neurological Sciences and Vision, ASST Spedali Civili, Brescia, Italy.
Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Owensboro, Italy.

Francesco Arba (F)

Stroke Unit, AOU Careggi, Firenze, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH